Immune cell clues may unlock better HS treatment

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject aged 18 to 65 years (included) * Subject able to read, understand and give documented informed consent * Subject willing and able to comply with the protocol requirements for the duration of the study * Subject with health insurance coverage according to local regulations * For woman with childbearing potential, negative pregnancy test at the inclusion visit Specific criteria for HS patients * Subject diagnosed with HS for at least 6 months * Subject diagnosed with moderate-to-severe HS defined by IHS4 score \> 4 * Subject is planned to be treated within 7 days with either adalimumab or secukinumab or bimekizumab under the conditions defined by the French National Health Authority * Normal chest imaging within 6 months prior to inclusion. * Negative Quantiferon test within 6 months prior to inclusion. * Negative HIV, HBV, and HCV serologies within 6 months prior to inclusion. * Presence of at least one active inflammatory lesion located outside a strict anatomical fold and outside the face, which will be selected for lesional skin biopsy Specific criteria for control patients * Subject diagnosed with plaque psoriasis or back-acne or impetigo Exclusion Criteria: * \- Pregnancy or breast-feeding women * Subject treated by immunosuppressive/immunomodulatory substances including oral corticosteroid or biological agents within 4 weeks before inclusion * Subject with any additional condition that, in the opinion of the investigator, may interfere with the assessment or put the subject at risk * Linguistic or mentally incapacity to sign the consent form * Subject protect by the law (adult under guardianship, or hospitalized in a public or private institution for a reason other than study, or incarcerated) * Subject in an exclusion period from a previous study or who is participating in another clinical trial * Weight \<50 kg * Diabetes * Specific treatments such as metformin or GLP1-agonist that may interfere with MAIT cell activity * History of allergic reaction to local anesthetic product * History of wound healing disorders (e.g. hypertrophic scars, keloids) * Subject treated by oral or topical antibiotics within 2 weeks before inclusion